48th week of 2017 patent applcation highlights part 9 |
Patent application number | Title | Published |
20170340622 | METHOD OF DETECTING CANCER STEM CELL, METHOD OFSCREENING CANCER STEM CELL, AND METHOD OF INHIBITING CANCERSTEM CELL - An object of the present invention is to provide a cancer cell inhibitory drug, particularly a cancer stem-cell inhibitory drug, or a cancer stem-cell detection probe. The present invention provides a cancer cell inhibitory drug comprising at least one compound represented by general formula (1) as an active ingredient | 2017-11-30 |
20170340623 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS - The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract. | 2017-11-30 |
20170340624 | Liposomes Useful for Drug Delivery - The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. | 2017-11-30 |
20170340625 | COMPOSITION AND METHOD FOR TREATING SKIN CONDITIONS - Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described. | 2017-11-30 |
20170340626 | OXYCODONE FORMULATIONS - The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C | 2017-11-30 |
20170340627 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions are provided which comprise effective amounts of an analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic. | 2017-11-30 |
20170340628 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES - Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor. | 2017-11-30 |
20170340629 | MASITINIB COMBINATION FOR USE IN TREATING BREAST CANCER - Disclosed is a method for treating breast cancer in a subject in need thereof, including administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with a therapeutically effective amount of a chemotherapeutic agent. | 2017-11-30 |
20170340630 | BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER - Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described. | 2017-11-30 |
20170340631 | BTK INHIBITORS - The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders. | 2017-11-30 |
20170340632 | Bromocriptine Formulations - The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes. | 2017-11-30 |
20170340633 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA - Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo. | 2017-11-30 |
20170340634 | Trk-INHIBITING COMPOUND - The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. | 2017-11-30 |
20170340635 | COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH A QUINAZOLINE DERIVATIVE - A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with 4-[(S)-2-azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide. | 2017-11-30 |
20170340636 | COMPOSITIONS AND METHODS FOR INHIBITION OF AUTOPHAGY - The present invention concerns compounds and their use to treat cell proliferative disorders including tumor growth and metastasis. Compounds of the present invention act as inhibitors of TAOK2 and modulators of autophagy, thereby functioning as anti-cancer or cancer-preventative therapeutic agents. | 2017-11-30 |
20170340637 | SOLID DISPERSIONS OF LOW-WATER SOLUBILITY ACTIVES - Disclosed are compositions including a solid dispersion comprising a dispersion polymer, a basic low-water solubility active, and an anionic counterion, as well as methods of making and using the compositions. | 2017-11-30 |
20170340638 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Provided is a composition of a ready-to-use injectable solution comprising pemetrexed or pharmaceutically acceptable salts thereof, containing pemetrexed; anhydrous sodium sulfite; and N-acetyl-L-cystein. With respect to use as an injectable preparation. The ready-to-use injectable solution composition is suitable for effective administration of pemetrexed since a melting process of main ingredients is not necessary before administration, and the composition can be used by being diluted immediately in a perfusate. In addition, the properties of the composition do not change even in long-term storage, and pharmaceutical stability is significantly improved by inhibiting related substances below a reference, whereby the composition can be stored in a liquid preparation state. | 2017-11-30 |
20170340639 | PHARMACEUTICAL COMPOSITION OF PEMETREXED - The present invention relates to pharmaceutical composition comprising pemetrexed, a ready to use injection comprising pemetrexed. Liquid composition of pemetrexed comprises head space oxygen less than 5%, dissolved oxygen less than 2ppm and individual impurity level less than 0.2%. | 2017-11-30 |
20170340640 | METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE - Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: | 2017-11-30 |
20170340641 | HETEROCYCLYLAMINES AS PI3K INHIBITORS - The present invention provides heterocyclylamine derivatives of Formula I: | 2017-11-30 |
20170340642 | COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR - The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection. | 2017-11-30 |
20170340643 | VASOPROTECTIVE AND CARDIOPROTECTIVE ANTIDIABETIC THERAPY - The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease. | 2017-11-30 |
20170340644 | OPHTHALMIC AQUEOUS COMPOSITION - An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance. | 2017-11-30 |
20170340645 | COMBINATIONS OF MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES - A pharmaceutical composition comprising: | 2017-11-30 |
20170340646 | Methods and Compositions for Decreasing Gastric Emptying - Disclosed in certain embodiments is a method of decreasing gastric emptying comprising administering to a subject an effective amount of a sodium-channel blocker to decrease gastric emptying. | 2017-11-30 |
20170340647 | Preservative-free Treprostinil Formulations and Methods and Devices for Use with Same - This invention provides for a unit dosage form of treprostinil at a dosage of between 0.1 mg/mL and 25 mg/mL in a sterile fluid composition formulated for subcutaneous or intravenous injection, which composition does not comprise an antimicrobial preservative. Selectively activatable patch-pump assemblies comprising a sealed prefilled drug-reservoir containing the unit dosage form is described as are methods for reducing pain at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof, and methods of reducing irritation, inflammation or a combination thereof at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof. The invention also provides a method of treating pulmonary hypertension, and methods for treating, or reducing the severity or reducing the pathogenesis of Pulmonary arterial hypertension (PAH) in a subject making use of the compositions as herein described. | 2017-11-30 |
20170340648 | Pharmaceutical Compositions Affecting Bioenergetic Processes in a Eukaryotic Biological System and Methods of Treatment - Provided herein are methods for treating diseases and/or disorders and/or medical conditions with pharmaceutical compositions consisting of an association of active principles that affect metabolic processes in a eukaryotic biological system. Also provided herein are methods for the preparation of said pharmaceutical compositions for use in the methods of the embodiments of the present invention. Also provided herein are novel dosing strategies for administering the pharmaceutical compositions that constitute embodiments of the present invention. | 2017-11-30 |
20170340649 | TOPICAL AQUEOUS SPRAY COMPOSITIONS OF HALOBETASOL - The present invention relates to topical aqueous spray compositions of halobetasol. The topical aqueous spray compositions may be in the form of solutions or emulsions. It also relates to processes for the preparation of the topical aqueous spray compositions. It further relates to a method of treating topical skin conditions by administering said topical aqueous spray compositions. | 2017-11-30 |
20170340650 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY - Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: | 2017-11-30 |
20170340651 | COMPOSITION, FORMULATIONS AND METHODS OF MAKING AND USING BOTANICALS AND NATURAL COMPOUNDS FOR THE PROMOTION OF HEALTHY BRAIN AGING - The present disclosure provides compositions and formulations comprising botanicals and natural compounds for the promotion of healthy brain aging in adults and for prevention or inhibition of age associated neurodegenerative changes resulting in cognitive, memory and executive dysfunction including modulation of the age related predisposition to mild cognitive impairment, Alzheimer's disease, hormonal and other dementia related conditions. The present disclosure also provides methods of using the compositions and formulations in treating and preventing neurodegenerative changes resulting in cognitive, memory and executive dysfunction. | 2017-11-30 |
20170340652 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS - A pharmaceutical composition comprising a CHK inhibitor, and an Hsp90 inhibitor according to the following formulae or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein. | 2017-11-30 |
20170340653 | (R)-3-((3S,4S)-3-FLUORO-4-(4-HYDROXYPHENYL)PIPERIDIN-1-YL)-1-(4-METHYLBENZ- YL)PYRROLIDIN-2-ONE AND ITS PRODRUGS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS - The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system. | 2017-11-30 |
20170340654 | CRYSTALLINE DIFUCOSYLLACTOSE - Crystalline difucosyllactose, useful in a pharmaceutical composition and a nutritional composition, is disclosed. | 2017-11-30 |
20170340655 | ANTHRACYCLINE FORMULATIONS - The invention relates to reconstituted formulations comprising an anthracycline compound, ethanol, and water. The invention also relates to injectable compositions comprising the reconstituted formulation and Lactated Ringer's solution. Additionally, the invention relates to methods of using the formulations and compositions. | 2017-11-30 |
20170340656 | Non-Invasive Imaging Methods for Patient Selection for Treatment with Nanoparticulate Therapeutic Agents - Methods for providing treatment of pathologic conditions with nanoparticulate therapeutic agents are disclosed. Novel methods for determining liposomal deposition at sites of pathology using non-invasive imaging are also disclosed. | 2017-11-30 |
20170340657 | PALATINOSE FOR ENHANCING DIETARY SUPPLEMENT AND PHARMACEUTICAL DELIVERY - The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of a compound into the bloodstream, cells and tissue comprising administering palatinose, or a derivative thereof, in combination with the compound. The present invention also relates to a diluent for parenteral compounds. The diluent comprises palatinose or a derivative thereof. Another aspect of the present invention is directed to a method of decreasing the recovery time to pre-performance levels of total adenosine triphosphate (ATP) levels in a mammal comprising administering palatinose or a derivative thereof, to the mammal. The present invention is further directed to a method of supplying a compound to a diabetic patient, burn victim patient or trauma victim patient. The method comprises administering palatinose, or a derivative thereof, in combination with the compound. | 2017-11-30 |
20170340658 | COMBINED USE OF A CHEMOTHERAPEUTIC AGENT AND A CYCLIC DINUCLEOTIDE FOR CANCER TREATMENT - A kit of parts includes a) gemcitabine or a pharmaceutically acceptable salt thereof and b) a cyclic dinucleotide or pharmaceutically acceptable salt thereof, wherein the cyclic dinucleotide or pharmaceutically acceptable salt thereof is an agonist of the receptor known as “stimulator of interferon genes” (STING), for use in the treatment of solid pancreatic cancer. | 2017-11-30 |
20170340659 | POLYMALIC ACID-BASED NANOBIOPOLYMER COMPOSITIONS - Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described. | 2017-11-30 |
20170340660 | Non-Reducing End Unsaturated Mannuronic Acid Oligosaccharides And Compositions Containing Same As Active Ingredient - Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 Da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides. | 2017-11-30 |
20170340661 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder. | 2017-11-30 |
20170340662 | WEIGHT REDUCING COMPOSITION - The invention relates to soft drink industry, in particular, to dietetic nutrition. The inventive weight reducing composition comprises 0.01-10 mg/l of sodium and 25-150 mg/l of magnesium, the rest being water. Said composition (drinking water) makes it possible to reduce weight without altering the usual eating habits. In addition, consumption of said drinking water results in reduction of weight by 1.2-2.9 kg. | 2017-11-30 |
20170340663 | MINERAL COMPLEX FORMULATIONS FOR ORAL ADMINISTRATION AND METHODS FOR THEIR USE - The invention provides an oral formulation for dietary supplementation comprising a binder and a mineral complex consisting essentially of a natural basaltic deposit having an average particle size ranging from about 10 to about 6000 mesh and comprising about 40 wt. % to about 60 wt. % Si0 | 2017-11-30 |
20170340664 | Citrate Containing Beverage - Provided are beverage compositions comprising a urine citrate increasing component and a urine oxalate reducing component. The beverage compositions may be provided in a ready-to-drink form or may be provided in a concentrate form. Also provided are kits comprising the beverage compositions and methods for treating various conditions using the beverage compositions. | 2017-11-30 |
20170340665 | NANOPARTICLES AND THEIR USE IN CANCER THERAPY - The present invention provides a nanoparticle comprising a core comprising a metal; and a corona comprising a plurality of ligands covalently linked to the core, the plurality of ligands including at least a first species of ligand comprising an ethylene glycol portion and an amine group and at least a second species of ligand comprising a carbohydrate group, for use in a method of treating a cancer, particularly skin cancer, in a mammalian subject. Also disclosed are methods of treatment by administering the nanoparticles alone or in combination with radiotherapy. | 2017-11-30 |
20170340666 | BIOACTIVE GLASS MICROSPHERES - An aluminoborate composition, an alumino-borosilicate glass composition, or a mixture thereof, and solid or hollow microspheres thereof, as defined herein. Also disclosed are methods of making and using the disclosed compositions, for example, forming microspheres for use in bioactive applications, and composition extracts for use in treating or healing wounds. | 2017-11-30 |
20170340667 | COMPOSITIONS AND METHODS FOR TOPICAL TREATMENT OF TAR RESPONSIVE DERMATOLOGICAL DISORDERS - Compositions and methods for treating tar-responsive dermatological disorders are described. In particular, an anhydrous tar composition including a liquid wax and a therapeutically effective amount of tar in an anhydrous solvent, the composition being in liquid form at room temperature is described. The anhydrous tar composition can be topically applied to skin of a subject for treatment of tar-responsive dermatological disorders, such as psoriasis, eczema, atopic dermatitis, seborrheic dermatitis and pruritus. | 2017-11-30 |
20170340668 | NOVEL PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR TREATING LUNG INJURY - Disclosed are a novel pharmaceutical composition and use thereof, the novel pharmaceutical composition at least comprising an effective amount of mitochondria and at least one pharmaceutically acceptable carrier; the novel pharmaceutical composition is administered to an individual to send the mitochondria into injured or subject-to-oxidative-stress lung cells; thus treating or improving lung injury or related diseases thereof. | 2017-11-30 |
20170340669 | TOLEROGENIC DENDRITIC CELLS, METHODS OF PRODUCING THE SAME, AND USES THEREOF - Described herein are methods for the preparation of stable semi-mature tolerogenic dendritic cells and compositions comprising such stable semi-mature tolerogenic dendritic cells. The stable semi-mature tolerogenic dendritic cells described herein and compositions thereof can be used for the establishment of immune tolerance when treating an autoimmune disease, graft rejection and/or graft-versus-host disease. | 2017-11-30 |
20170340670 | CD11 B[low] MACROPHAGES AND CONDITIONED MEDIA THEREOF FOR TREATING CANCER AND/OR FIBROSIS - A conditioned cell culture medium of CD11b | 2017-11-30 |
20170340671 | Blood Plasma and Plasma Fractions as Therapy for Tumor Growth and Progression - The invention relates to treating individuals with cancer by using blood plasma or blood plasma fractions as treatment. | 2017-11-30 |
20170340672 | CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOF - The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided. | 2017-11-30 |
20170340673 | LYSATES OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF SKELETAL MUSCLE INJURIES - The present invention relates to the use of the intracellular content of mesenchymal stem cells in individuals for stimulating the survival, regeneration and/or repair of the damaged organ and/or tissue. The present invention also relates to the use of said lysate for producing a pharmaceutical composition comprising said intracellular content, and to the use thereof in the regeneration and/or repair of the damaged organ and/or tissue. | 2017-11-30 |
20170340674 | PREVENTION OF PROGRESSIVE HEART FAILURE - The present disclosure relates to methods for preventing progressive heart failure in subjects with persistent left ventricular (LV) dysfunction. Such methods may also be used for treating or preventing progressive heart failure in subjects with a proximal left anterior descending (LAD) lesion and persistent left ventricular dysfunction. | 2017-11-30 |
20170340675 | CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF ACUTE STROKE - A method for the treatment of acute stroke in a subject by administering to said subject an effective amount of a cell-based composition containing a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml. | 2017-11-30 |
20170340676 | CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF DIABETES AND ASSOCIATED METABOLIC DISORDERS AND FOR AMELIORATION OF INSULIN RESISTANCE IN PRE-DIABETES - The present invention relates to a cell-based composition comprising a suspension of mesenchymal stem cells in crystalloid with a cellular concentration from 0.01 million to 3.0 million cells/ml. The cell-based composition is used in a form of medicament for treatment of diabetes and its associated metabolic disorders and complications. | 2017-11-30 |
20170340677 | METHOD FOR PRODUCING THERAPEUTIC CORNEAL ENDOTHELIAL SUBSTITUTE CELL SPHERE - The problem of the present invention is to provide a method of efficiently producing therapeutic alternative corneal endothelial cells, particularly, a method capable of stably producing them in a condition suitable for intraocular transplantation (in the anterior chamber) in a large amount. Furthermore, the present invention aims to provide a composition for transplantation, which is preferable for intraocular administration, particularly, into the anterior chamber. A therapeutic alternative corneal endothelial cell sphere can be produced by culturing stem cells in suspension in a differentiation induction medium containing a GSK3 inhibitor, retinoic acid and a ROCK inhibitor. Addition of a viscoelastic substance during intraocular (into the anterior chamber) transplantation of the sphere or cultured corneal endothelial cells dispersed into single cells can increase the number of adherent cells after transplantation. | 2017-11-30 |
20170340678 | SERUM-FREE AND XENOGEN-FREE HUMAN CARDIAC EXPLANT-DERIVED STEM CELLS AND USES AND METHODS FOR THE PRODUCTION THEREOF - Methods for generating serum-free and/or xenogen-free cardiac explant-derived stem cells (EDC) are provided. These methods may include providing an initial cardiac explant, which has been minced and digested; plating the initial cardiac explant; culturing the plated cardic explant in serum-free and xenogen-free medium; harvesting EDC cells surrounding or emerging from the plated cardiac explant; and optionally performing static expansion of harvested EDC cells in serum-free and xenogen-free media. Serum-free and/or xenogen-free cardiac EDC cells produced by these methods, as well as methods and uses thereof for the treatment of heart failure in a subject in need thereof, are also provided. | 2017-11-30 |
20170340679 | ANTIVENOM COMPOSITIONS AND USES THEREOF - Disclosed herein are compositions and methods for treating a victim of a venomous snakebite. Antivenom compositions are prepared from snake plasma or from snake eggs. The antivenom compositions are able to neutralize a snake venom from an autologous snake. The antivenom compositions can be administered to a snakebite victim to treat or prevent the pathological effects of a venomous snakebite. | 2017-11-30 |
20170340680 | USE OF A PARTICULAR EXTRACT OF PROPOLIS FOR COMBATING THE SIDE EFFECTS OF CHEMOTHERAPY - The invention relates to the use of a composition comprising at least one extract of propolis, having at least one of the following properties:—an antioxidant value (ORAC) greater than or equal to 500 mmol TE/100 g of dry extract,—a flavones and flavonols content greater than or equal to 5.5% by weight with respect to the total weight of dry material of the extract,—a flavanones and dihydroflavanols content greater than or equal to 5% by weight with respect to the total weight of dry material of the product, in order to prevent and/or limit the side effects of chemotherapy. | 2017-11-30 |
20170340681 | USE OF STREPTOCOCCUS THERMOPHILIS TCI633 IN TREATING ARTHRITIS - A method of treating arthritis, which comprising administering to a subject in need an effective amount of | 2017-11-30 |
20170340682 | BACILLUS COMPOSITIONS AND METHODS OF USE WITH RUMINANTS - strains, compositions and methods are disclosed for reducing growth of microorganisms in a feed. | 2017-11-30 |
20170340683 | BACILLUS SUBTILIS STRAIN WITH PROBIOTIC ACTIVITY - The current invention concerns a new | 2017-11-30 |
20170340684 | TETRAFUNCTIONAL BACTERIOPHAGE - The invention provides a recombinant targeted bacteriophage for expressing a transgene in a target cell transduced with the bacteriophage. The bacteriophage comprises a first nucleic acid sequence encoding a pill capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the bacteriophage to a target cell, a second nucleic acid sequence encoding at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon, and a transgene which encodes a protein which exerts a biological effect on the target cell. | 2017-11-30 |
20170340685 | NOVEL CLOSTRIDIUM PERFRINGENS BACTERIOPHAGE CLO-PEP-1 AND USE THEREOF FOR INHIBITING PROLIFERATION OF CLOSTRIDIUM PERFRINGENS - The present invention relates to a Myoviridae bacteriophage Clo-PEP-1 that is isolated from the nature and can kill | 2017-11-30 |
20170340686 | NOVEL SHIGATOXIN-PRODUCING F18 TYPE E. COLI BACTERIOPHAGE ESC-COP-1 AND USE THEREOF FOR INHIBITING PROLIFERATION OF SHIGATOXIN-PRODUCING F18 TYPE E. COLI - The present invention relates to a Myoviridae bacteriophage Esc-COP-1 that is isolated from the nature and can kill specifically Shigatoxin-producing type F18 | 2017-11-30 |
20170340687 | NOVEL GENETICALLY ENGINEERED VACCINIA VIRUSES - The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination. | 2017-11-30 |
20170340688 | TITRATED EXTRACTS OF CYNARA SCOLYMUS AND USES THEREOF - The present invention relates to a titrated extract of | 2017-11-30 |
20170340689 | TITRATED EXTRACTS OF CYNARA SCOLYMUS FOR USE IN THE TREATMENT OF MESOTHELIOMA - The present invention relates to a titrated extract of | 2017-11-30 |
20170340690 | METHOD FOR IMPROVING INTESTINAL HEALTH USING EXTRACTS OF CODONOPSIS LANCEOLATA - Disclosed is a method for improving intestinal microflora, which includes administering an extract of | 2017-11-30 |
20170340691 | An Antimicrobial Composition - The present invention provides an antimicrobial composition comprising at least one garlic extract and one or more of a bioflavonoid and/or an organic acid as well as the use of the same for treating or preventing bacterial, fungal or parasitic infections. | 2017-11-30 |
20170340692 | COMPOSITION FOR LYMPH DRAINAGE - The present invention relates to a mixture of active ingredients consisting of | 2017-11-30 |
20170340693 | DISLODGEMENT AND RELEASE OF HSC USING ALPHA 9 INTEGRIN ANTAGONIST AND CXCR4 ANTAGONIST - Haematopoietic stem cell mobilization is a process whereby haematopoietic stem cells are stimulated out of the bone marrow space. Before HSC can mobilize, they must be dislodged and released from the BM stem cell niche in which they reside and are retained by adhesive interactions. Accordingly, in an aspect of the present invention there is provided a method for enhancing dislodgement of HSC and their precursors and progenitors thereof from a BM stem cell binding ligand in vivo or ex vivo, said method comprising administering in vivo or ex vivo an effective amount of an antagonist of an α9 integrin or an active portion thereof and a CXCR4 antagonist or an active portion thereof to the BM stem cell niche. Once mobilized to the peripheral blood (PB) the HSC may be collected for transplant. Methods which enhance mobilization of the HSC can also improve treatments of haematological disorders. | 2017-11-30 |
20170340694 | COMPOSITION FOR PROMOTING METALLOTHIONEIN PRODUCTION - The present disclosure relates to a composition to aid in heavy metal detox. Metallothioneins (MT) are a family of cysteine-rich enzymes in the body that help remove and regulate heavy metals, copper, and other metals. Amino Acids in combination with zinc and/or molybdenum may provide improved production of MT over amino acid or zinc supplements alone. Additionally, Vitamin B6, Molybdenum, and Boron may be included to further enhance the efficacy of the composition. | 2017-11-30 |
20170340695 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT NEUROPATHY - The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition. | 2017-11-30 |
20170340696 | CHEMOTHERAPEUTIC COMBINATIONS OF CATIONIC ANTIMICROBIAL PEPTIDES AND CHEMOTHERAPEUTICS - The present invention provides a compound, preferably a peptide, having the following characteristics: a) consisting of 9 amino acids in a linear arrangement; b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group; c) at least one of said 9 amino acids is a non-genetically coded amino acid (e.g. a modified derivative of a genetically coded amino acid); and optionally d) the lipophilic and cationic residues are arranged such that there are no more than two of either type of residue adjacent to one another; and further optionally e) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues; for use in the treatment of a tumour by combined, sequential or separate administration with a cytotoxic chemotherapeutic agent that inhibits immune tolerance, wherein the chemotherapeutic agent is administered at a sub-cytotoxic dose. The present invention further provides pharmaceutical packs or compositions comprising these active agents and methods of treating a tumour comprising administration of these active agents. | 2017-11-30 |
20170340697 | SELECTIVE NOX-1 INHIBITOR PEPTIDES AND USES THEREOF - The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging. | 2017-11-30 |
20170340698 | CYCLIC PEPTIDE SPECIFICALLY BINDING TO APOPTOTIC CELLS AND USE THEREOF - Provided is a cyclic peptide (cyclo [Cys-Gln-Arg-Pro-Pro-Arg-Cys] peptide) comprised of the amino acid sequence of SEQ ID NO: 2; and a composition for apoptotic cell detection, drug delivery or imaging, containing the same as an active ingredient. The cyclic peptide (cyclo [Cys-Gln-Arg-Pro-Pro-Arg-Cys] peptide has an excellent effect of binding to apoptotic cells, compared with a linear peptide thereof, thereby greatly facilitating the detection of apoptotic cells and the in vivo imaging of an affected part under apoptosis, while the detection and imaging signal shows a very high correlation in disease prognosis prediction. The cyclic peptide binds to an imaging material, early diagnosing a response of a drug for treating diseases associated with abnormal cell proliferation, and binds to a therapeutic material, selectively delivering a drug to tissues afflicted with Apoptosis-associated diseases. | 2017-11-30 |
20170340699 | Adenovirus AD36 E4ORF1 Protein For Prevention and Treatment of Non-Alcoholic Fatty Liver Disease - This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of Adenovirus 36 E4orf1 protein or functional variant thereof. | 2017-11-30 |
20170340700 | USE OF AN ANTIMICROBIAL PEPTIDE TP4 IN TREATING A CANCER - The preset invention relates to a new approach for treating a cancer, particularly a malignant tumor, a multidrug-resistant (MDR) cancer, a recurrent cancer or a metastatic cancer, using a specific cationic antimicrobial peptide (CAP), tilapia piscidin 4 (TP4), which is derived from Nile Tilapia ( | 2017-11-30 |
20170340701 | CELL-PERMEABLE PEPTIDE SYSTEM FOR TREATING DISEASES CAUSED BY GLUTAMATE EXCITOTOXICITY - Peptide system including at least one peptide blocking the presynaptic release of glutamate. The peptide has the sequence SEQ ID NO 5: GRKKRRQRRRPPIEQSIEQEEGLNRS and/or sequence SEQ ID NO 8: GRKKRRQRRRPPMSEYNATQSDYRER for use in treating pathologies associated with glutamate excitotoxicity. | 2017-11-30 |
20170340702 | METHODS FOR DIAGNOSING AND TREATING SYSTEMIC LUPUS ERYTHEMATOSUS - Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis. | 2017-11-30 |
20170340703 | TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA - The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule. | 2017-11-30 |
20170340704 | Cell - The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22. | 2017-11-30 |
20170340705 | Cell - The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22. | 2017-11-30 |
20170340706 | LOCALLY RELEASED GROWTH FACTORS TO MEDIATE MOTOR RECOVERY AFTER STROKE - Methods of improving recovery of a mammal after an ischemic event (e.g., stroke) are provided. In various embodiments the methods involve administering a neural growth factor (e.g., BDNF) into the infarct (e.g., stroke) cavity in a biocompatible hydrogel formulation. In certain embodiments the hydrogel comprises a thiolated hyaluronan and a thiolated gelatin with an optional thiolated heparin. | 2017-11-30 |
20170340707 | System and Method for Multiphasic Release of Growth Factors - A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth factor in a sustained release profile. The initial release profile releases at least one growth factor over a period of hours to days, wherein the growth factor is released in a large amount initially, with the remainder being released in progressively lower amounts. The sustained release profile releases at least one growth factor over a period of days to weeks, wherein the growth factor is released at a generally constant amount over such period. The system of the invention is particularly suited for applications on bioimplants. The invention also comprises methods and kits for multiphasic delivery of at least one growth factor. The invention also comprises calcium sulphate as a carrier for releasing at least one growth factor in both single and multiphasic systems for delivering at least one growth factor at a treatment site. | 2017-11-30 |
20170340708 | PROTEINACEOUS HETERODIMER AND USE THEREOF - The present disclosure provides proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof. | 2017-11-30 |
20170340709 | METHODS OF TREATMENT USING STEM CELL MOBILIZERS - The present invention relates to the field of stem cells. In one aspect, the present invention provides methods of treating a subject with acute liver injury comprising administering to the subject a therapeutically effective amount of at least one stem cell mobilizer. In particular embodiments, the subject is treated with plerixafor and G-CSF | 2017-11-30 |
20170340710 | USE OF HEPCIDIN AS A REGULATOR OF IRON HOMEOSTASIS - The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload while inhibitors of hepcidin can be used in the treatment of anaemia. | 2017-11-30 |
20170340711 | Articular Cartilage Mimetics - A scaffold for promoting cartilage formation is provided that includes a crosslinked electrospun fiber, wherein the crosslinked electrospun fiber consists essentially of crosslinked gelatin. The crosslinked electrospun fiber is generally crosslinked with a crosslinker, and the crosslinker may be diisosorbide bisepoxide. The crosslinked electrospun fiber may be crosslinked by adding a crosslinker to a solution of gelatin at a desired concentration. The electrospun fiber may advantageously remain intact for 18 days or longer upon being immersed in an aqueous solution. A composition for promoting cartilage formation is also provided that includes the disclosed scaffold and a mesenchymal stem cell (MSC). The disclosed scaffold may include a crosslinked electrospun fiber that includes gelatin and sodium cellulose sulfate (NaCS), e.g., in an amount of up to 5% by weight of the amount of gelatin. A method for promoting cartilage formation is also provided that includes administering to a subject in need thereof a disclosed composition for promoting cartilage formation in the subject. | 2017-11-30 |
20170340712 | CAMKK1 AS A NOVEL REGENERATIVE THERAPEUTIC - Disclosed herein are methods of treating an ischemic or inflammatory condition in an organ or tissue of a patient comprising inducing an increase of the level of CAMKK1 in said organ or tissue. | 2017-11-30 |
20170340713 | Compositions for Treating Pathological Calcification Conditions, and Methods Using Same - The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria. | 2017-11-30 |
20170340714 | Compositions for Treating Pathological Calcification Conditions, and Methods Using Same - The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria. | 2017-11-30 |
20170340715 | Materials and Methods Useful For Treating Glioblastoma - The present invention provides compositions and methods useful for treating cancers such as glioblastoma. SapC-DOPS was found to be synergistically effective at inducing cell death when administered in conjunction with rampamycin. SapC-DOPS/rapamycin combination therapy allows physicians to give lower doses of each drug and achieve better therapeutic efficacy. The compositions also allow for less toxicity and fewer off-target effects. Related methods and materials are also provided herein. | 2017-11-30 |
20170340716 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ASTHMA - The present invention provides compounds and methods for treating or preventing pulmonary diseases include COPD and asthma. In particular, the present invention provides for compounds comprising type V collagen, or tolerizing fragments thereof, for the treatment of COPD and asthma. | 2017-11-30 |
20170340717 | MSI-SPECIFIC FRAMESHIFT PEPTIDES (FSP) FOR PREVENTION AND TREATMENT OF CANCER - Described is a vaccine for prevention and treatment of cancer characterized by microsatellite instability (MSI). The vaccine contains an MSI-specific frameshift peptide (FSP) generating humoral and cellular responses against tumor cells or a nucleic acid encoding said FSP. The vaccine of the present invention is particularly useful for the prevention/treatment of colorectal cancer, endometrial cancer, gastric cancer or small bowel cancer. | 2017-11-30 |
20170340718 | NOVEL POLYSACCHARIDE AND USES THEREOF - Provided herein is a novel | 2017-11-30 |
20170340719 | IMMUNOGENIC COMPOSITION - The present invention relates to immunogenic compositions comprising a | 2017-11-30 |
20170340720 | COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - An effective | 2017-11-30 |
20170340721 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES - Compositions and methods are described for generating an improved effective immune response against an immunogen in humans. The enhanced immune response, is obtained by using an MVA vector as a prime and an adenovirus vector as a boost and is characterized by a high level of antibody response specific to the immunogen, and an enhanced cellular immune response. The compositions and methods can be used to provide a protective immunity against a disease, such as an infection of one or more subtypes of Ebola and Marburg filoviruses, in humans. | 2017-11-30 |